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It is a known phamarcogenetic phenomenon that drug responses
differ signiﬁcantly between different races. Genetic mutation in a
gene which codes for a drug-metabolizing enzyme can cause
enzyme variations with high, low or no activity. The cytochrome
P450 enzymes, a superfamily of hemoproteins, are the terminal
oxidases of the mixed function oxidase system found on the
membrane of the smooth endoplasmic reticulum preferentially
expressed in the centrilobular area of the liver [1]. The cytochrome
P450 isoenzymes in families 1–3 are responsible for 70–80% of all
phase I-dependent metabolism of clinically used drugs [2–4] and
also participate in the metabolism of a large number of xenobiotic
chemicals. The human CYP2Cs are among the most important
subfamilies within the CYP superfamily, which metabolize nearly
20% of clinically used drugs.
CYP2C9 is the most important member of the CYP2Cs, and it
hydroxylates about 15% of drugs [5] in current clinical use. The
CYP2C9 gene codes for a signiﬁcant drug-metabolizing enzyme whichhas a series of prescribed drugs as its substrates, including drugs with
a narrow therapeutic index such as S-warfarin, tolbutamide and
phenytoin [6,7]. Impaired CYP2C9 catalytic activity can cause
difﬁculties in drug efﬁcacy and toxicity. Because of their narrow
therapeutic index, dosage adjustment of these drugs based on CYP2C9
genotype, especially at the beginning of therapy, could help to lower
the risk of concentration-dependent drug toxicity in variant carriers.
CYP2C9 also metabolizes other routinely prescribed drugs such as
acenocoumarol, losartan, glipizide, and a large number of nonsteroi-
dal anti-inﬂammatory drugs, including diclofenac and ibuprofen [5,8].
The enzyme activity of CYP2C9 is therefore a critical factor in
pharmacotherapy.
To date, though more than 30 variant CYP2C9 alleles have been
identiﬁed, CYP2C9*2 and *3 are the most prevalent and can inﬂuence
drug clearance and drug response. In vitro, for some drugs, the
substrate afﬁnity of CYP2C9*2 (Arg144Cys) variants is not signiﬁ-
cantly affected [5]; but for some other drugs such as acenocoumarol,
the catalytic activity of CYP2C9*2 is severely decreased [9]. There is a
signiﬁcant reduction of the catalytic activity in the CYP2C9*3
(Ile359Leu) variant, with only around 10% of the intrinsic clearance
of the wild-type enzyme for most CYP2C9 substrates [9,10]. In
addition, the frequencies of the related SNPs are different in different
races. In Caucasians, higher frequencies of CYP2C9*2 and CYP2C9*3
alleles are observed (10.7% and 7.4% respectively) [11], compared
with African-Americans (1% and 0.5%, respectively) [12]. The
CYP2C9*2 allele has rarely been detected in Asian populations. It has
been found to have a frequency of 13% in Iran [13] but has not been
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Japan. The allelic frequency of the CYP2C9*3 variant is also
signiﬁcantly lower among Asians compared with other groups.
While the frequencies of mutant alleles of CYP2C9, in particular the
CYP2C9*2 and CYP2C9*3 polymorphisms, have been studied exten-
sively in other major populations, there is no comprehensive
information on polymorphisms of the gene for the Chinese Han
population. As the largest population in the world (nearly 20%), the
Chinese Han population is spread over the third largest populated
area with a land mass of about 9.6 million square kilometer. In
addition, the Han have an extremely long and complex demographic
history and the population stratiﬁcation arising from the interplay of
different geographic areas will therefore have inﬂuenced the
polymorphism pattern. A previous study by our group found that a
cryptic borderline was observable between the Southern Han and the
Northern Han populations [14]. However, no polymorphism study of
the CYP2C9 gene focusing on the different geographic Han popula-
tions has been carried out to date.
To establish a database of CYP2C9 allele frequencies for the healthy
Chinese Han population, which would be useful for personalized
medicine, we decided to systematically screen the polymorphisms of
the CYP2C9 gene including the 5’-ﬂanking region, all exons and their
neighboring intron regions and the 3’ UTR in the four different
geographic Chinese Han populations covering the north, south, east
and west of Chinese mainland.
2. Result
Wedetected a total of 27 different polymorphisms from400 Chinese
Han population samples, 3 of which were novel. All the allele and
genotype frequencies were analyzed using the SHEsis analysis platform
andwere found to be in equilibriumwith theHardy-Weinberg equation.
We found ﬁve polymorphisms in the 5’-ﬂanking region. Tfsitescan
analysis (http://www.ifti.org) revealed no altered transcription factor
binding efﬁciency. In the coding region, we found seven polymor-
phisms, including 1 novel synonymous one (T1137→C, p.379Tyr→-
Tyr). 11 polymorphismswere detected in the introns, one of whichwas
novel (42461 TNC). We did some splice analysis of the intronic (or
exonic) SNPs, but still obtained no positive results. We also found three
polymorphisms in the 3’-UTR region, one of which was novel (1739-
1740ATdel) (Fig. 1), and which has the potential to inﬂuence the
stability of CYP2C9 mRNA. We made a statistical comparison of all theFig. 1. Sequencing result for 1739-1740ATdel mutatiopolymorphism frequencies in the four different geographic populations.
The comparison revealed some SNPs with signiﬁcant differences
(pb0.0001) between the four geographic populations. The frequencies
of all thepolymorphisms are summarized in Table 1 and the p-values for
the four populations in Table 2.
More than 30 CYP2C9 alleles and 400 genotypes have been
reported. In our study, we found 6 CYP2C9 alleles and 11 genotypes in
the mainland Chinese Han population. The most frequent alleles were
the wild-type allele *1(92%), followed by the *3 allele (4.6%) and the
*8 allele (1.8%). Some allele frequencies were low (b1%), such as the
*2 allele (0.6%), the *11 allele (0.1%) and the *31 allele (0.9%). Some
alleles had signiﬁcantly different frequencies across the four different
geographical populations, such as the *2 and *8 alleles. We found
these two SNPs in Shanghai and Shenyang populations, but not in
those of Shantou or Xi'an areas. Allele *11 was detected only in Xi'an
population, and allele *31 was detected in Shantou and Shenyang
populations. The results are shown in Table 3. The genotype
frequencies are shown in Table 4.
We compared the allele and genotype frequencies with other
major populations, including Asians and non-Asians, as shown in
Table 5. Most populations we analyzed had 3 major alleles namely
allele *1, allele *2, and allele *3, each with different frequencies,
possibly reﬂecting the differences in racial make-up and the different
geographical areas. We also performed the haplotype analysis, but it
was a lack that we didn't ﬁnd any interesting results.
3. Discussion
CYP2C9 plays a very important role in cytochrome P450 genetic
diversity and in the metabolism of prescribed drugs. It would
therefore be advantageous to have an assessment of a patient's
CYP2C9 metabolic status before initiation of therapy to identify the
risk of nonresponse to therapy or toxic drug effects and to ensure
optimal dosage. While the frequencies of mutant alleles of CYP2C9
have been studied in other populations, little comprehensive
information on genetic polymorphisms of the CYP2C9 gene has
been available for the Chinese Han population. Our study provides
new data on CYP2C9 polymorphism in this population and compares
the incidence of polymorphisms among subjects from four different
geographic areas of Chinesemainland aswell as with those from other
different racial and ethnic populations. This could contribute
signiﬁcantly toward a better understanding of the polymorphismsn: (A) wild type and (B) heterozygous mutation.
Table 1
Positions and frequencies of CYP2C9 polymorphisms in the Chinese population.
Position⁎ Reference Region Effect Minor allele frequency (%)
Shantou Shanghai Shenyang Xi'an Chinese
−1911 TNC rs9332092 5′-ﬂanking region Not translated T(C) 2.3 6.8 5.7 2.8 4.5
−1885 CNG rs9332093 5′-ﬂanking region Not translated C(G) 2.3 6.8 5.7 2.8 4.5
−1537 GNA rs61604699 5′-ﬂanking region Not translated G(A) 2.4 4.7 5.8 3.3 4.1
−1188 CNT rs4918758 5′-ﬂanking region Not translated T(C) 38.6 34.8 34.7 29.0 34.4
−981ANG rs59890169 5′-ﬂanking region Not translated G(A) 6.2 5.6 1.6 4.9 4.6
3411 TNC rs9332120 Intron 2 Not translated T(C) 0 0 2.2 0 0.3
3497 CNG Intron 2 Not translated C(G) 0 1.0 0 0 0.3
430 CNT rs1799853 exon 3 R144C C(T) 0 1.0 1.1 0 0.6
449 GNT rs7900194 exon 3 R150H G(T) 0 2.6 3.9 0 1.8
9032 CNG rs9332127 Intron 3 Not translated G(C) 0.7 3.8 0.6 1.1 1.6
10311ANG rs9332129 Intron 4 Not translated A(G) 2.6 4.1 1.2 2.4 2.6
10376 TNC Intron 4 Not translated T(C) 1.3 4.6 1.9 0.6 2.1
42461 TNC novel Intron 6 Not translated T(C) 1.3 0 0 0 0.1
980 TNC rs57505750 exon 7 I327T T(C) 0.6 0 3 0 0.9
1003 CNT rs28371685 exon 7 R335T C(T) 0 0 0 0.6 0.1
1075ANC rs1057910 exon 7 I359L A(C) 1.3 6.9 4.8 4.9 4.6
1137 TNC novel exon 7 synonymous T(C) 0 0.5 0 0 0.1
42726 CNT rs17847029 Intron 7 Not translated C(T) 12.0 3.7 6.6 2.4 6.1
47545ANT rs9332230 Intron 8 Not translated A(T) 2.3 6.5 2.2 6.2 4.4
47639 CNT rs2298037 Intron 8 Not translated C(T) 27.8 26.6 9.2 33.3 24.5
50056ANT rs1934969 Intron 8 Not translated A(T) 29.6 5.2 25.3 0.6 14.5
50125 CNT Intron 8 Not translated C(T) 0 0.6 0 0 0.1
1425ANT rs1057911 exon9 synonymous A(T) 1.2 5.2 4.0 3.3 3.4
1581 CNG rs9332242 3′-UTR Not translated C(G) 0 0 1.1 0 0.3
1693ANG rs9332244 3′-UTR Not translated A(G) 1.2 0 1.1 0 0.6
1739-1740ATdel novel 3′-UTR Not translated ATdel 1.2 0.6 0 0 0.4
50742 TNA rs9332245 3′near gene T(A) 1.2 6.7 4.7 3.2 3.9
*The position in the gene is according to the reference sequences of NG_008385.1 and NM_000771.3 in the GeneBank.
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One novel SNP was detected in the 3’-UTR region and it may have
an impact on the stabilization of mRNA transcription. The CYP2C9 *8
and *11 were ﬁrst found in Asian populations while they have already
been found in African-American [15,16]. CYP2C9*8 (Arg150His) and
CYP2C9*11 (Arg335Trp) can both cause a decrease in the activity of
CYP2C9 in vivo [17,18]. While in vitro studies showed that CYP2C9*8
(Arg150His) had an increase of its activity comparing with a
decreased activity of CYP2C9*11 (Arg335Trp) [15,16]. Still, theTable 2
CYP2C9 allele frequencies in the four different geographical Chinese populations.
SNP p-value
ST:SH ST:SY ST:XA SH:SY SH:XA SY:XA
−1911 TNC 0.026413 0.10181 0.748611 0.520595 0.052063 0.179777
−1885 CNG 0.043988 0.10181 0.748611 0.67327 0.083454 0.179777
−1537 GNA 0.241952 0.108255 0.595156 0.62879 0.507031 0.259433
−1188 CNT 0.448308 0.266058 0.980384 0.062151 0.457799 0.250911
−981ANG 0.024783 0.083483 0.043602 0.600962 0.80129 0.779832
3411 TNC – 0.058388 – 0.038228 – 0.07653
3497 CNG 0.195491 – – 0.172197 0.22585 –
430 CNT 0.194212 0.178755 – 0.938975 0.22585 0.208389
449 GNT 0.039844 0.011281 – 0.471118 0.054418 0.017698
9032 CNG 0.065166 0.941169 0.695522 0.047378 0.091539 0.631566
10311ANG 0.45054 0.374985 0.914402 0.105961 0.379102 0.427245
10376 TNC 0.079452 0.683057 0.525844 0.157624 0.021835 0.302698
980 TNC 0.271654 0.115923 0.304505 0.025161 – 0.016584
1003 CNT – – 0.331814 0.313692 0.283683 –
1075ANC 0.010193 0.064576 0.061821 0.980173 0.420954 0.404917
42726 CNT 0.00354 0.093842 0.000847 0.06792 0.489684 0.214749
47545ANT 0.050576 0.974358 0.061696 0.045487 0.914196 0.055735
47639 CNT 0.796469 pb0.0001 0.253925 p 0.0001 0.156518 pb0.0001
50056ANT pb0.0001 0.394061 pb0.0001 pb0.0001 0.010288 pb0.0001
50125 CNT 0.310799 – – 0.302326 0.291488 –
1425ANT 0.03698 0.101912 0.187812 0.608739 0.378577 0.714982
1581 CNG – 0.16589 – 0.160952 – 0.142803
1693ANG 0.151299 0.962677 0.133614 0.160952 – 0.142803
50742 TNA 0.009597 0.056563 0.208859 0.429882 0.119423 0.448227functional activity of CYP2C9*31 (Ile327Thr) is unknown both in
vivo and in vitro. This has relevance for the study of CYP2C9 gene
polymorphisms in the Chinese Han population and could be helpful
for future pharmacogenomics and pharmacokinetics studies in Asian
populations generally.
In our polymorphism analysis, the prevalence of *2 and *3 is in
accordance with previous reports [19]. Some allele and genotype
frequencies showed differences among the four different populations,
which differ in their cultural variants and other factors, such as living
environment, dietary habits, and even folk customs. Systematic
analysis of the connections between the polymorphisms and the
different geographical populations can give us a map of the
polymorphism distribution over the whole Han population and
would be useful for personalized medicine in China.
We compared the allele and genotype polymorphisms in the
Chinese Han population with other ethnic populations and found that
the allele frequencies detected in our Han population are similar to
those in Asian groups, such as the Tamilnadu and South Indian
populations [20,21]. However, CYP2C9*2, which we detected in our
study, has not been reported in the Korean and Japanese populations
[22,23], and CYP2C9*3, which we also identiﬁed, is absent in the
Iranian population [13]. Several alleles (*8, *11) are not found in other
Asian populations such as Korean and Japanese, while the Beninese
and Belgian population have *11 (2.7% and 0.4%, respectively)[24]. AsTable 3
CYP2C9 allele frequencies in the four different geographical Chinese populations.
CYP2C9
allele*
Allele frequency (%)
Shantou Shanghai Shenyang Xi'an Chinese
*1 98.1 89.5 87.2 94.5 92.0
*2 0 1.0 1.1 0 0.6
*3 1.3 6.9 4.8 4.9 4.6
*8 0 2.6 3.9 0 1.8
*11 0 0 0 0.6 0.1
*31 0.6 0 3.0 0 0.9
*The alleles which are not showed in this table are not identiﬁed in our study.
Table 4
CYP2C9 genotype frequencies in the four different geographical Chinese populations.
CYP2C9
genotype
Genotype frequency (%)
Shantou Shanghai Shenyang Xi'an Chinese
*1/*1 95.0 81.7 83.1 86.2 85.9
*1/*2 0 0 2.6 0 0.8
*1/*3 3.3 11.8 7.8 9.8 8.3
*1/*8 0 3.9 0 0 1.1
*1/*31 1.7 0 3.9 0 1.5
*2/*3 0 1.3 0 0 0.4
*2/*8 0 1.3 0 0 0.4
*3/*3 0 0 0 2.0 0.4
*3/*8 0 0 1.3 0 0.4
*3/*11 0 0 0 2.0 0.4
*3/*31 0 0 1.3 0 0.4
Table 6
Primers and ampliﬁcations.
Primer Region 5 →3 Product (nt)
F21 −2138 to −1632 5 -cagatatcccttctatctacac-3 507
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activity, and we calculated their total frequency across the Chinese
population at 6.5%. Signiﬁcant differences were found between the
Han Chinese and non-Asian populations. These results indicate
signiﬁcant differences in polymorphism distributions between Asian
and non-Asian populations.
In summary, we systematically screened the polymorphisms of the
whole CYP2C9 gene in four different geographical Han populations of
mainland China. This is the ﬁrst systematic screening of genetic
polymorphisms of CYP2C9 in the Chinese Han population, and is the
largest CYP2C9 genotyping study using direct sequencing in China.
We have provided new data on the genetic polymorphism of the
CYP2C9 gene, which can help to establish a database for further
functional research and for personalized medicine in the Chinese
population.
4. Materials and methods
4.1. Subjects
The study subjects consisted of 400 Chinese healthy unrelated
volunteers from four geographical area of the Chinese mainland: 100
subjects from Xi'an city which lies in the west of china; 100 subjects
from Shanghai city which lies in the east of china; 100 subjects from
Shenyang city which lies in the north of china; 100 subjects from
Shantou city which lies in the south of china. Each group of 100Table 5
Comparison of CYP2C9 allele frequencies in different ethnic groups.
Population n CYP2C9 allele (%) Ref.
*1 *2 *3 *5 *8 *11 *31
Chinese 400 92.0 0.6 4.6 0 1.8 0.1 0.9
Asians
Korean 574 98.9 0 1.1 [23]
Tamilnadu 135 90.7 2.6 6.7 [20]
South Indian 346 88.0 4.0 8.0 [21]
Iranian 200 87.2 12.8 0 [13]
Japanese 436 97.9 0 2.1 [22]
Malay 209 95.7 1.9 2.4 [25]
Non-Asians
Egyptian 247 82.0 12.0 6.0 [26]
White-American 140 82.5 13.2 4.3 [27]
African-American 600 86.7 2.8 2.0 4.7 1.3 [15,16]
British 100 79.0 12.5 8.5 [28]
Spanish 102 74.5 15.6 9.8 [29]
Swedish 430 81.9 10.7 7.4 [11]
French Caucasians 151 77.0 15.0 8.0 [19]
Italian 360 77.8 12.5 9.7 [30]
Turkish 499 79.4 10.6 10.0 [31]
Beninese 111 95.5 1.8 2.7 [24]
Belgian 121 82.2 12.0 7.4 0.4 [24]
Ashkenazi Jewish 250 77.2 14.0 8.6 0.2 [32]subjects consisted of 50 males and 50 females between 18 and
53 years of age. All subjects were judged to be in good health in terms
of their medical history and following a physical examination. All
participants gave ethnic information about themselves, conﬁrming
their parents and grandparents to be of the same origin. The four
different populations were frequency-matched to each other in terms
of age and sex. An explanation of the study was given to the
participating subjects and they gave a standard informed consent,
which was reviewed and approved by the Shanghai Ethical Commit-
tee of Human Genetic Resources. All subjects were Han Chinese in
origin.4.2. Polymerase chain reaction conditions and DNA sequencing
The systematic polymorphism screening was performed using
direct sequencing. Genomic DNA was isolated from peripheral blood
using the standard procedure. The PCR primers were designed to
amplify the 2000 bp of the 5’-ﬂanking regions and all exons of the
CYP2C9 gene. To insure that all the regions we chose were analyzed,
the PCR ampliﬁcation regions in the 5’-ﬂanking region overlapped
each other. The primers are listed in Table 6. The PCR was carried out
on the Gene Amp® PCR system 9700 (Applied Biosystems, CA, USA) in
a total volume of 15 μL containing 10 ng of genomic DNA, 10 mM Tris-
HCl (pH 8.3), 50 mM KCl, 1.5–3.0 mM MgCl2, 200 mM dNTP, 1 mM of
each primer and 0.25U Taq DNA polymerase. The cycling protocol
consisted of denaturation at 95 °C for 1 min, followed by 30–35 cycles
at 95 °C for 30 s, 50–65 °C for 1 min, 72 °C for 1 min, and a ﬁnal
extension at 72 °C for 10 min. Preparation of DNA for sequencing
included incubation of PCR products with 0.1 U of shrimp alkaline
phosphatase (Roche, Basel, Switzerland) and 0.5 U of exonuclease I
(New England Biolabs Inc., MA, USA) at 37 °C for 45 min, followed by
heat inactivation at 85 °C for 20 min. The PCR products were
sequenced using an ABI Prism® BigDye Terminator Cycle Sequencing
Kit, version 3.1 (Applied Biosystems, CA, USA) on an ABI Prism 3100
sequencer.R21 5 -gctgggactagaacccataa-3
F22 −1819 to −1216 5 -atctagtcaactggggctgta-3 625
R22 5 -ggaggtagggaaatcactaaat-3
F23 −1350 to −693 5 -gaaaatggctttgcacaagtat-3 657
R23 5 -cctgggagaacaggacacc-3
F24 −991 to −365 5 -cagtcatggagaagggagat-3 626
R24 5 -agattaataaccagttgggaata-3
F25 -540 to 99 5 -ttcatgtttaggctgctgtatt-3 639
R25 5 -ggggccaggagggagtttt-3
F1 exon1 5 -atttatccatcaaagaggcaca-3 486
R1 5 -atctaacatgcaaagacccaaa-3
F2 exon2 5 -attgtctgaccattgccttga-3 583
R2 5 -gccggatctccttccattt-3
F3 exon3 5 -tgaaacccatagtggtgctg-3 611
R3 5 -cacaaatatgtgcaaattccct-3
F4 exon4 5 -tttaaccagctaggttgtaatg-3 621
R4 5 -agaaacagggctttggagttt-3
F5 exon5 5 -ggaaatgattatcatctggttag-3 660
R5 5 -tagtttatatttctgtgggctc-3
F6 exon6 5 -gcaagcatggaataagggag-3 603
R6 5 -gccaggctggtcttgaact-3
F7 exon7 5 -gtgcatctgtaaccatcctct-3 595
R7 5 -taagagtagccaaaccaatctt-3
F8 exon8 5 -aagcttgatgaaaaggaggac-3 642
R8 5 -tctcaatttggaagaattggatt-3
F91 exon9 5 -atttttcagttgcctatacatcc-3 653
R91 5 -gctaagtatgagcattatgtgac-3
F92 exon9–3’-UTR 5 -ctctgtgccgcccttctac-3 584
R92 5 -ctttcaaatccaatcctaaagta-3
281Y. Xiong et al. / Genomics 97 (2011) 277–2814.3. Statistical analysis
All of the polymorphisms were named based on the nucleotide
reference sequence (NG_008385.1) and the protein reference
sequences (NP_000762.2). Allele and genotype frequencies were
calculated by the counting method. Comparisons of allele and
genotype frequencies among different geographic populations or
between the Chinese population and other ethnic populations were
done using χ2 tests or Fisher's exact tests with a signiﬁcance level set
at 0.05. Hardy–Weinberg equilibrium calculations and p-value
between each of two loci were performed using the SHEsis analysis
platform (http://analysis.bio-x.cn/myAnalysis.php).
4.4. Automated splice site analysis
The strengths of splice sites for the corresponding splicing
mutations were evaluated using web-based software (https://splice.
cmh.edu).
4.5. Analysis of functional sequences in the promoter region
The transcription factor binding analysis of the polymorphisms in
the 5'untranslated region (UTR) was performed on the web-based
Tfsitescan software based on the transcription factor binding sites
database. The normal and mutant sequences were analyzed sepa-
rately. The inﬂuence of the polymorphisms was inferred by the
comparison of the results of the normal and mutated sequences.
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